Search

Researchers at Royal Pearl Hospital in Tamil Nadu, India, conducted a study on Juvenile Nasopharyngeal Angiofibroma (JNA), a benign but locally aggressive tumor with a rich blood supply. The study aimed to evaluate the efficacy of ligating feeding vessels based on preoperative imaging to reduce blood loss during surgery, potentially eliminating the need for preoperative embolization. The findings showed that preoperative imaging accurately identified feeding vessels, and ligation of these vessels significantly reduced blood loss compared to studies using preoperative embolization. This research offers a targeted approach to surgery for JNA, potentially improving outcomes for patients. [Extracted from the article]

A recent study conducted at the All India Institute of Medical Sciences (AIIMS) in Rajasthan, India, focused on cellular angiofibroma (CA), a rare benign soft tissue tumor that primarily affects the vulvoperineal region. The research highlighted a case of vaginal CA in a 40-year-old woman who initially presented with pressure symptoms and was clinically suspected to have a vaginal myoma. The study emphasized the importance of accurate diagnosis through histomorphology and immunohistochemistry, as CA can be mistaken for other benign and aggressive spindle cell tumors in the same area. For more information, the full article can be accessed in the Journal of Mid-life Health. [Extracted from the article]

A recent study conducted at the Dmitry Rogachev National Medical Research Center for Pediatric Hematology focused on neoadjuvant therapy for juvenile angiofibroma, a vascular tumor that primarily affects children and young men. The study highlighted a case of a 16-year-old boy with severe symptoms who showed significant improvement after 9 months of treatment with Sirolimus. The research, published in the journal Opuholi golovy i šei, emphasized the successful clinical outcome of the neoadjuvant therapy in reducing the tumor size and improving the patient's vision. [Extracted from the article]

A recent study conducted at Peking Union Medical College Hospital has reported a rare case of cellular angiofibroma occurring in the pelvic cavity of a 25-year-old female patient. Cellular angiofibroma is a benign mesenchymal tumor that typically occurs in the genital area, making its occurrence in the pelvis extremely rare. The patient underwent surgical excision of the tumor, and no recurrence has been observed four months after the procedure. The study suggests that cellular angiofibroma should be considered in the differential diagnosis of hypervascular pelvic space-occupying lesions, and treatment typically involves local excision of the tumor followed by postoperative monitoring. [Extracted from the article]

A recent report from the University of Laval in Quebec, Canada discusses a novel technique for the treatment of Von Willebrand Disease in a pediatric patient with a massive juvenile angiofibroma (JNA). The standard treatment for JNA is surgical resection, often preceded by embolization. However, standard embolization may not completely devascularize the tumor. In this case, the researchers used a direct intratumoral onyx embolization technique, which safely allowed for complete tumor devascularization and subsequent resection. The study suggests that this technique is safe and effective, even in cases where little vascularization comes from internal carotid artery branches. [Extracted from the article]

A recent study conducted at Heidelberg University Hospital in Germany has found that helium ion therapy (HRT) shows promise as a treatment for advanced juvenile nasopharyngeal angiofibroma (JNA). The study compared HRT to proton therapy (PRT) and found that HRT led to enhanced target coverage and reduced radiation-induced complications. Specifically, HRT resulted in a reduction in ocular toxicity, cataract development, xerostomia, tinnitus, alopecia, and delayed recall. Additionally, HRT showed a mean excess absolute risk reduction of approximately 30% for secondary central nervous system malignancies. This research suggests that HRT may be a beneficial treatment option for advanced JNA, with the potential for reduced complications. [Extracted from the article]

A recent study conducted by researchers from the University of New South Wales in Sydney, Australia, focused on the treatment of angiofibromas in individuals with tuberous sclerosis complex (TS). The study found that while mammalian target of rapamycin inhibitors have greatly improved the management of angiofibromas, laser treatment is still necessary for stubborn lesions. The researchers conducted a systematic review of 47 articles, which included a total of 217 patients with TS-related facial angiofibroma who received laser treatment. The study concluded that different lasers, such as potassium titanyl phosphate, pulsed dye, and neodymium-doped: yttrium aluminum garnet, are better suited for managing the vascular and fibrous components of angiofibromas, but no single laser was found to be superior. [Extracted from the article]

A study conducted at a Hospital and Research Centre has found that topical sirolimus, an mTOR inhibitor, is an effective treatment for facial angiofibromas in patients with tuberous sclerosis complex (TSC). TSC is a rare autosomal dominant disorder, and facial angiofibromas are the most common cutaneous findings of the condition. The study included four patients who applied sirolimus preparation twice daily for three months, resulting in a reduction in the Facial Angiofibroma Severity Index (FASI) score. The researchers concluded that topical sirolimus is a beneficial therapy for facial angiofibromas in TSC patients. [Extracted from the article]

A recent study conducted at Lokmanya Tilak Municipal Medical College and General Hospital in Maharashtra, India, explored the use of a multimodal blood loss prevention bundle (MBLPB) during surgery for juvenile nasopharyngeal angiofibroma (JNA). The researchers found that while the MBLPB did not significantly reduce blood loss, it did result in high surgeon satisfaction. The study involved 20 patients who underwent 23 surgeries, and the median estimated blood loss was 1300 ml. The findings suggest that further research is needed to develop more effective strategies for reducing blood loss during JNA surgery. [Extracted from the article]

Researchers from Dalian Medical University have published a case report and literature review on tuberous sclerosis complex (TSC), a rare genetic disorder characterized by hamartomas and neoplastic lesions in various organ systems. The study focuses on the incidence of giant cell angiofibroma (GCA) in TSC patients, which is extremely rare. The researchers present the first case of GCA in the gingival tissue of a TSC patient and emphasize the need for further case reports to better understand the relationship between GCA and TSC. The findings contribute to a better understanding of this rare disease. [Extracted from the article]

A recent study conducted at Aga Khan University in Karachi, Pakistan, has highlighted the successful use of 3D printing technology in the field of otolaryngology. The study focused on a case of a 19-year-old male with a rare tumor called juvenile nasopharyngeal angiofibroma. The patient underwent angioembolization and endoscopic surgical resection, with the surgeon utilizing a patient-specific 3D-printed biomodel to visualize the tumor and plan the procedure. The researchers concluded that incorporating 3D-printed biomodels in surgical practice can lead to improved outcomes for patients. [Extracted from the article]

A study conducted at Angers University Hospital in France examined the efficacy and safety of topical rapamycin in reducing facial angiofibromas in patients with tuberous sclerosis complex (TSC). The researchers used a cream formulation produced by the hospital's pharmacy and surveyed 79 TSC patients about their perceptions of the treatment. The results showed that the topical rapamycin was well-tolerated and effective in the short-, medium-, and long-term, with high ratings for both efficacy and safety. This study supports the use of topical rapamycin as a treatment for facial angiofibromas in TSC patients. [Extracted from the article]

A systematic review conducted by researchers at McMaster University Medical Center in Hamilton, Canada, examined cases of early-onset Juvenile Nasopharyngeal Angiofibroma (JNA), a fibrovascular tumor of the nasopharynx that typically affects adolescent males. The review identified 34 cases of early-onset JNA, with a mean age of diagnosis of 8.15 years old. Patients in this cohort appeared to have more advanced disease and higher recurrence rates compared to reported averages. The researchers hope that this review will increase clinical awareness of this potentially more aggressive subtype of JNA. [Extracted from the article]